Title:Ferroptosis Inhibitors as Potential New Therapeutic Targets for Cardiovascular
Disease
Volume: 22
Issue: 17
Author(s): Zahra Shaghaghi, Shokouh Motieian, Maryam Alvandi, Amirhossein Yazdi, Bahareh Asadzadeh, Soghra Farzipour*Sahar Abbasi
Affiliation:
- Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
- Department of Pharmaceutical Biotechnology,
School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
Keywords:
Ferroptosis inhibitors, cardiovascular diseases, lipoxygenase inhibitors, reactive oxygen species, iron chelators, antioxidants.
Abstract: Ferroptosis is a novel form of programmed cell death that occurs due to an increase in iron
levels. Ferroptosis is implicated in a number of cardiovascular diseases, including myocardial infarction
(MI), reperfusion damage, and heart failure (HF). As cardiomyocyte depletion is the leading
cause of patient morbidity and mortality, it is critical to thoroughly comprehend the regulatory mechanisms
of ferroptosis activation. In fact, inhibiting cardiac ferroptosis can be a useful therapeutic
method for cardiovascular disorders. The iron, lipid, amino acid, and glutathione metabolisms strictly
govern the beginning and execution of ferroptosis. Therefore, ferroptosis can be inhibited by iron chelators,
free radical-trapping antioxidants, GPX4 (Glutathione Peroxidase 4) activators, and lipid peroxidation
(LPO) inhibitors. However, the search for new molecular targets for ferroptosis is becoming
increasingly important in cardiovascular disease research. In this review, we address the importance
of ferroptosis in various cardiovascular illnesses, provide an update on current information
regarding the molecular mechanisms that drive ferroptosis, and discuss the role of ferroptosis inhibitors
in cardiovascular disease.